TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Chronic Heart Failure Health Status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Pain Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Patient adherence to heart failure-specific self care practices
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Proportion of OGTTs falsely negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct detection of upright posture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IgG levels in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in spot urine protein/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction of symptom distress
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: International Cooperative Ataxia Rating Scale (ICARS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity of adjTIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in blood oxygenation level dependent (BOLD) patterns of brain blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Perceptions about participation in clinical trials
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: re-hospitalization rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Diagnostic performance (specificity and sensitivity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of febrile bacteremia due to Gram-negative germs multi-resistant to antibiotics
Endpoint domain: Adverse events/effects
Primary endpoint: Decision-making skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sexual Desire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Oral pigmentation index (DOPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Melanin pigmentation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Gingival Appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Patient Fatigue Scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in blood pressure level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence and severity of TEAEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: change in best corrected ETDRS-visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Sample of Sufficient Volume to Yield a Valid Meter Reading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Lancing Pain for Device Pair at Visit 2
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: ALK mutation detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: T790M EGFR mutation detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: proportion of patients receiving second cycle of catumaxomab
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC[0-t]) of GSK3640254
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Joint Angle Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Child PTSD Symptom Scale (CPSS-5) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients who received anakinra
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of severe chimeric antigen receptor T-cell-related encephalopathy syndrome (ICANS)
Endpoint domain: Adverse events/effects
Primary endpoint: Expression of intestinal mucosal receptors involved in nociceptive information transmission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: level of ibuprofen in bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of ibuprofen in synovial membrana
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of ibuprofen in synovial fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Postoperative Recovery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: appetite profile ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fatty acid composition in red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Vocal biomarker performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean brain temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EQ-5D
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain relief at the knee and hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days for gametocytes to become undetectable
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Muscle Tissue PGC1alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Muscle Tissue AMPK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Muscle Tissue LKB1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Apnea Hypopnea Index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Acceptance rate of comprehensive eye examination
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Number of Incontinence Episodes Per 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke volume variation (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulse pressure variation (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Symptoms of upper gastrointestinal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Endoscopy examination of upper gastrointestinal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fecal examination of upper gastrointestinal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Patients Tumor Progression Free and Alive at Four Months
Endpoint domain: Mortality/survival
Primary endpoint: Patient's knowledge about opioids
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cerebral SEP response (P300)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peri-implant tissue reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AMH levels in IBD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: E2 levels in IBD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: FSH levels in IBD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AFC levels in IBD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma levels of branched chain amino acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma Trimethylamin N-oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma level of acetyl-CoA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Amount of bone labial to the implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Horizontal labio-palatal bone width
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Vertical bone dimensional changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rejection Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in body weight measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Clinical Global Improvement Scale Rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blood Pressure Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with substantial pain related impairment of function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain related impairment of function at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Satisfaction with the mobile application
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-monitoring of coagulation effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: laryngoscopic visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Forced Expiratory Volume in 1 second (FEV-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Engagement level with the tracker
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in lung Standard uptake value (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Distribution Volume Ratio (DVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of recurrent orofacial herpes episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Effect of Piperacillin/Tazobactam infusion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of subcutaneously given dexmedetomidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of elsulfavirine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of VM1500A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of rifampicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of clarithromycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With at Least One Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cotinine validated quit rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Introperative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of blood transfusions required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AUC 0-tz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of subjects with drug-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Plasma Concentration of Drospirenone (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Analyte Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration of Drospirenone (AUC [0-last])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Analyte Concentration-time Curve From Time Zero to Infinite Time of Drospirenone (AUC [0-infinity])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until patient's care in the hospital after stroke's symptoms
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of patients with disease response or progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence and clinical course of Parkinson Disease (PD) motor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average Change in Visual Acuity (Letters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood clinical parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of symptom reoccurrence (relapse)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Remaining on Spironolactone at Week 12
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Locoregional tumour control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pharmacodynamics (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total hydromorphone consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction of postprandial Oxidized LDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Full Scale IQ (FSIQ)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Verbal IQ (PIQ)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Performance IQ (PIQ)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Postoperative pain 7 days after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Progression to Type 2 Diabetes Mellitus (T2DM) During Treatment Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Varicella Zoster Virus (VZV) Seroprotective Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum consumption of dioxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sexual Health Communication Checklist score - Parents
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Sexual Health Communication Checklist score - Child
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: cure of stress incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intra-operative complications
Endpoint domain: Adverse events/effects
Primary endpoint: PD-L1 Prevalence IHC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD-L1 Prevalence ICC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD-L1 Detection in Pleural Effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Tasks of Daily Living - Revised
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adults Subjective Assessment of Participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in NRS pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in HbA1c at 104 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in Knee Society Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Knee range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: inflammatory cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in quadriceps muscle size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinical improvement based on the 7-point scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower Murray lung injury score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Adherence to exercise training intervention
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adherence to dietary nitrate intervention
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Perceived difficulty of training sessions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Side effect monitoring
Endpoint domain: Adverse events/effects
Primary endpoint: Cost of treatments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Keratometric Correction Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Refractive Correction Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Restaged Upwards
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Subjects With an Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Tumor Necrosis Factor (TNF) Alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Interleukin (IL) 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Urinary Tetranor Prostaglandin D Metabolite (PGDM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in White Blood Cell Numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Mean Score of Depressive Symptoms using the CES-D Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Mean Score of Perceived Stress Scale (PSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Mean Score of Parental Sense of Competence using PSOC Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: degree of hepatic steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: ISGA Score of Clear (0) or Almost Clear (1) for Scalp Involvement at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient / Caregiver Satisfaction Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median Percent Change in Focal Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum observed concentration (Cmax) of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T)) of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in capillary blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to antibiotic administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the computer algorithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Specificity of the computer algorithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of intestinal colonization of patients with CPE 3 months after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cumulative whole blood bactericidal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ADAMTS13 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: global mortality rate
Endpoint domain: Mortality/survival